Mostrar el registro sencillo del ítem

dc.contributor.authorKattar, A.*
dc.contributor.authorQuelle-Regaldie, A.*
dc.contributor.authorSánchez, L.*
dc.contributor.authorConcheiro Nine, Ángel*
dc.contributor.authorAlvarez-Lorenzo, C.*
dc.date.accessioned2025-09-09T11:23:27Z
dc.date.available2025-09-09T11:23:27Z
dc.date.issued2023
dc.identifier.citationKattar A, Quelle-Regaldie A, Sánchez L, Concheiro A, Alvarez-Lorenzo C. Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery. Pharmaceutics. 2023;15(4).
dc.identifier.issn1999-4923
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/64609f3ac6d6be6c90fc6450
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21513
dc.description.abstractThe aim of this work was to develop niosomes for the ocular delivery of epalrestat, a drug that inhibits the polyol pathway and protects diabetic eyes from damage linked to sorbitol production and accumulation. Cationic niosomes were made using polysorbate 60, cholesterol, and 1,2-di-O-octadecenyl-3-trimethylammonium propane. The niosomes were characterized using dynamic light scattering, zeta-potential, and transmission electron microscopy to determine their size (80 nm; polydispersity index 0.3 to 0.5), charge (?23 to +40 mV), and shape (spherical). The encapsulation efficiency (99.76%) and the release (75% drug release over 20 days) were measured with dialysis. The ocular irritability potential (non-irritating) was measured using the Hen's Egg Test on the Chorioallantoic Membrane model, and the blood glucose levels (on par with positive control) were measured using the gluc-HET model. The toxicity of the niosomes (non-toxic) was monitored using a zebrafish embryo model. Finally, corneal and scleral permeation was assessed with the help of Franz diffusion cells and confirmed with Raman spectroscopy. Niosomal permeation was higher than an unencapsulated drug in the sclera, and accumulation in tissues was confirmed with Raman. The prepared niosomes show promise to encapsulate and carry epalrestat through the eye to meet the need for controlled drug systems to treat the diabetic eye.
dc.description.sponsorshipThis research was funded by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Actions (grant agreement-No 813440). The work was also supported by MCIN/AEI/10.13039/501100011033 [PID 2020-113881RB-I00 to A.C. and C.A.-L., and PID2020-115121GB-I00 to L.S.], Spain, Xunta de Galicia [ED431C 2020/17], and FEDER.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleFormulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery
dc.typeArtigo
dc.authorsophosKattar, A.; Quelle-Regaldie, A.; Sánchez, L.; Concheiro, A.; Alvarez-Lorenzo, C.
dc.identifier.doi10.3390/pharmaceutics15041247
dc.identifier.sophos64609f3ac6d6be6c90fc6450
dc.issue.number4
dc.journal.titlePharmaceutics*
dc.relation.projectIDEuropean Union [813440]
dc.relation.projectIDMCIN/AEI [PID 2020-113881RB-I00, PID2020-115121GB-I00]
dc.relation.projectIDFEDER [[ED431C 2020/17]
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics15041247
dc.rights.accessRightsopenAccess*
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number15


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)